Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients.
Cárdenas G, Chávez-Canales M, Espinosa AM, Jordán-Ríos A, Malagon DA, Murillo MFM, Araujo LVT, Campos RLB, Wong-Chew RM, González LER, Cresencio KI, Velázquez EG, de la Cerda MR, Leyva Y, Hernández-Ruiz J, Hernández-Medel ML, León-Hernández M, Quero KM, Monciváis AS, Díaz SH, Martínez IRZ, Martínez-Cuazitl A, Salazar INM, Sarmiento EB, Peña AF, Hernández PS, Reynoso RIA, Reyes DM, Del Río Ambriz LR, Bonilla RAA, Cruz J, Huerta L, Fierro NA, Hernández M, Pérez-Tapia M, Meneses G, Espíndola-Arriaga E, Rosas G, Chinney A, Mendoza SR, Hernández-Aceves JA, Cervantes-Torres J, Rodríguez AF, Alor RO, Francisco SO, Salazar EA, Besedovsky H, Romano MC, Bobes RJ, Jung H, Soldevila G, López-Alvarenga J, Fragoso G, Laclette JP, Sciutto E.
Cárdenas G, et al. Among authors: rodriguez af.
Trials. 2022 Feb 14;23(1):148. doi: 10.1186/s13063-022-06075-5.
Trials. 2022.
PMID: 35164840
Free PMC article.
Clinical Trial.